Regulation of tumor progression by anti-neoplastic T cell responses - PubMed (original) (raw)
Review
doi: 10.4161/cbt.3.2.758. Epub 2004 Feb 1.
Affiliations
- PMID: 14739786
- DOI: 10.4161/cbt.3.2.758
Review
Regulation of tumor progression by anti-neoplastic T cell responses
Scott I Abrams. Cancer Biol Ther. 2004 Feb.
Abstract
A central paradox in tumor immunology is the seeming coexistence of a developing or progressing tumor burden in the absence of a therapeutically effective host anti-neoplastic response. It is now generally thought, however, that the host, whether mouse or human, can mount a T cell response against a developing malignancy without any prior immunization. Ostensibly, the nature or potency of that antitumor response is frequently insufficient to alter the course of neoplastic progression. Consequently, cancer immunotherapy was born from the idea that a preexisting or newly induced immune response may be intensified to achieve clinical regression. At the heart of that matter is the capacity of the host immune system to not only phenotypically distinguish normal from malignant cells, but also to functionally mediate antitumor activity. In both preclinical models and clinical settings, a plethora of tumor-associated or tumor-specific antigens have now been identified that can induce anti-neoplastic CD4+ or CD8+ T cell responses. Thus, immunization against neoplastic disease is attainable and, in several cases, overcomes potential mechanisms of immune tolerance and escape. In terms of objective clinical responses, however, the results have been less dramatic, and only a smaller proportion of patients have undergone significant disease regression. These responses have been observed mainly in clinical settings of adoptive T cell therapy, as compared with vaccination approaches. Nonetheless, these studies collectively provide the rationale for the further development and application of active and adoptive immunotherapies, perhaps in combination with each other or with oncological interventions, to promote more meaningful and sustainable anti-neoplastic immune responses and clinical outcomes.
Similar articles
- Cancer immunogene therapy.
Yoshizawa H, Kagamu H, Gejyo F. Yoshizawa H, et al. Arch Immunol Ther Exp (Warsz). 2001;49(5):337-43. Arch Immunol Ther Exp (Warsz). 2001. PMID: 11798131 Review. - The generation and analyses of a novel combination of recombinant adenovirus vaccines targeting three tumor antigens as an immunotherapeutic.
Gabitzsch ES, Tsang KY, Palena C, David JM, Fantini M, Kwilas A, Rice AE, Latchman Y, Hodge JW, Gulley JL, Madan RA, Heery CR, Balint JP Jr, Jones FR, Schlom J. Gabitzsch ES, et al. Oncotarget. 2015 Oct 13;6(31):31344-59. doi: 10.18632/oncotarget.5181. Oncotarget. 2015. PMID: 26374823 Free PMC article. - TRICOM vector based cancer vaccines.
Garnett CT, Greiner JW, Tsang KY, Kudo-Saito C, Grosenbach DW, Chakraborty M, Gulley JL, Arlen PM, Schlom J, Hodge JW. Garnett CT, et al. Curr Pharm Des. 2006;12(3):351-61. doi: 10.2174/138161206775201929. Curr Pharm Des. 2006. PMID: 16454749 Review. - Cancer immunotherapy: a treatment for the masses.
Blattman JN, Greenberg PD. Blattman JN, et al. Science. 2004 Jul 9;305(5681):200-5. doi: 10.1126/science.1100369. Science. 2004. PMID: 15247469 Review. - Are Conventional Type 1 Dendritic Cells Critical for Protective Antitumor Immunity and How?
Cancel JC, Crozat K, Dalod M, Mattiuz R. Cancel JC, et al. Front Immunol. 2019 Feb 12;10:9. doi: 10.3389/fimmu.2019.00009. eCollection 2019. Front Immunol. 2019. PMID: 30809220 Free PMC article. Review.
Cited by
- Heterogeneity assessment of functional T cell avidity.
Ioannidou K, Baumgaertner P, Gannon PO, Speiser MF, Allard M, Hebeisen M, Rufer N, Speiser DE. Ioannidou K, et al. Sci Rep. 2017 Mar 13;7:44320. doi: 10.1038/srep44320. Sci Rep. 2017. PMID: 28287160 Free PMC article. - Development of ipilimumab: a novel immunotherapeutic approach for the treatment of advanced melanoma.
Wolchok JD, Hodi FS, Weber JS, Allison JP, Urba WJ, Robert C, O'Day SJ, Hoos A, Humphrey R, Berman DM, Lonberg N, Korman AJ. Wolchok JD, et al. Ann N Y Acad Sci. 2013 Jul;1291(1):1-13. doi: 10.1111/nyas.12180. Epub 2013 Jun 17. Ann N Y Acad Sci. 2013. PMID: 23772560 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Research Materials